

Age of Onset

All sections on this page are required unless otherwise specified. Important fields are highlighted. Incomplete information could result in a delay of testing.

PATIENT INFORMATION					
First Name	Last Name				
Sex Assigned at Birth O Male O Female Patient Karyotype (if known): Gender Identification (optional):	Date of Birth (mm/dd/	уу)			
Ancestry O Ashkenazi Jewish O His (optional) O Black/African American O Inc	ligenous Peoples OW	outh Asian /hite ther:			
Address					
City	State	Zip Code			
Primary Phone	Is this patient decease Deceased Date:				
O A A A DI E I A I	CODMATION				
	FORMATION Medical Record #				
Date Sample Collected (mm/dd/yy)	Medical Record #				
O Blood O Buccal Swab O Other (specif	·				
Patient has had a blood transfusion O Yes C (2-4 weeks of wait time is required for some to		tusion:			
Patient has had an allogeneic bone marrow tr Fibroblasts are required for patients who had a See www.genedx.com/specimen-requirement Patient has a personal history of a hematologi	an allogeneic bone mar ts for details.				
O Yes (specify diagnosis)		O No			
If yes, please call the lab to discuss with a gen sample type.	etic counselor the most	appropriate			
Treatment-Related RUSH (optional)					
Reason: OTransplantation OPregnancy	y O Surgery O Othe	er:			
	CONSENTS				
By signing this form, I acknowledge as the pa read or have had read to me the GeneDx Info this test requisition form, and understand the testing. I have had the opportunity to ask que the risks, and the alternatives. By signing this testing as ordered. I understand that, for tests members concurrently, test results from these single comprehensive report that will be made their healthcare providers. More information, including the GeneDx Notic website: www.genedx.com	rmed Consent docume information regarding i sitions about the testing form, I authorize Geneb: that evaluate data fror e family members may le available to all tested	nt at the end of molecular genetics I, the procedure, Ix to perform genetic In multiple family be included in a I individuals and			
By checking this box, I confirm that I am a I for GeneDx to retain any remaining sample of testing, and to be used as a de-identific improvement, internal validation, quality a New York law requires GeneDx to destroy nused for test development studies.	e longer than 60 days a ed sample for test devel ssurance, and training p	fter the completion opment and ourposes. Otherwise,			
□ Check this box if you wish to opt out of beir □ Check this box if you do not wish to receive Sequencing and Genome Sequencing Test	e ACMG secondary findi	ngs (Full Exome			
Signature of Patient/Legal Guardian (require	d)	Date			
Signature of Relative A/Legal Guardian		Date			
Signature of Relative B/Legal Guardian		Date			
FOR COMMERCIAL INSURANCE ONLY: By entering my preferred contact information contact me with an estimate of the patient's may apply.					
Email (required)*	Mobile Number				

*Contact information provided must be for the individual authorizing the genetic testing.

ACCOUNT INFORMATION					
GeneDx Account Num	ber	Account Name			
Phone		Fax			
Address		City			
State	Zip Code	Country			
Ordering Provider Nar	ne	<u> </u>	Role/Title		
NPI		Phone Number			
Send Report Via	O Fax O Email Fax #/Email:	○ Portal			
Additional Reporting F	Provider's Name (optio	nal)	Role/Title		
NPI					
Send Report Via	O Fax O Email Fax #/Email:	O Portal			
SEND ADDITIONAL REP	ORT COPIES TO (options	ıl)			
Provider Name		GeneDx Acct#			
Fax #/Email:					

STATEMENT OF MEDICAL NECESSITY

ICD-10-CM CODES

By submission of this test requisition and accompanying sample(s), I: (i) authorize and direct GeneDx to perform the testing indicated; (ii) certify that the person listed as the ordering provider is authorized by law to order the test(s) requested; (iii) certify that any custom panel and/or ordered test(s) requested on this test requisition form are reasonable and medically necessary for the diagnosis and/or treatment of a disease, illness, impairment, symptom, syndrome or disorder; (iv) the test results will determine my patient's medical management and treatment decisions of this patient's condition on this date of service; (v) have obtained this patient's and relatives', when applicable, written informed consent to undergo any genetic testing requested; and (vi) that the full and appropriate diagnosis code(s) are indicated to the highest level of specificity.

Signature of Ordering Provider

PAYMENT OPTIONS (Select One)						
OINSURANCE BILL Select all that apply Commercial Medicaid Medicare	Patient Status O Hospital outpati O Not a hospital p Name of Insurance	atient	inpat	ient; Date of Discho	arge:	
☐ Tricare ☐ CHAMPVA	Relationship to Ins O Self O Spou Policy Holder's Nai	ise OChild	0	Other: Policy Holder's Do	ate of Birth	
FOR ALL INSURANCE PROVIDE FRONT AND BACK COPY OF CARD(S)	Referral/Prior Authorization # (please attach) Secondary Insurance Type:			Hold test for cost estimate and contact patient if estimate is >\$100 (commerical insurance only)		
	Relationship to Ins	sured		scriber Name Other:	Date of Birth	
O PATIENT BILL	If Patient Bill is selected, I am electing to be treated as a self-pay patient for this testing. I agree that neither GeneDx nor I will submit a claim to my insurance for this testing, if I have insurance. GeneDx will send an invoice to the patient listed above.					
	Authorized Patient/Guardian Signature					
O INSTITUTIONAL BILL	GeneDx Account # Hospital/Lab Nam	•		Place Sticker/	Stamp Here	

ICD-10-CM Codes

Clinical Diagnosis



GeneDx Account	:#		Account Name						
First Name			Last Name Date of Birth				Date of Birth		
XOMEDX® TESTING OPTIONS									
TEST CODE	T CODE TEST NAME				CODE	TES	ΤN	IAME	
□ 561a	XomeDx® - Trio*			□ 690	а	Xom	neD.	0x® Plus - Trio* (XomeDx® + 690	c mtDNA)
☐ 561e	XomeDx® - Duo*			□ 690	е	Xom	neD.	Dx® Plus - Duo* (XomeDx® + 690	Oc mtDNA)
☐ 561b	XomeDx® - Proband			☐ 690l	b	Xom	neD.	x® Plus - Proband (<i>XomeDx</i> ® +	690c mtDNA)
If a Trio or Duo test is ordered, please fill out the Family Member Samples to be Included in Testing section below									
			XOMEDX® RE	EFLEX 1	FESTIN	G O	PTI	IONS	
TEST CODE	TEST NAME			TEST C	EST CODE TEST NAME				
□ 522	Reflex to FMR1 CGG Repeat	Analysis aft	er negative exome	□ 910		Refle	ex to	o Chromosomal Microarray (M	licroarrayDx) after negative exome
		FAMI	LY MEMBER SAM	PLES T	O BE IN	ICLL	UDI	ED IN TESTING	
codes may re		tely corresp	ond with family men	nber sar					THE PROBAND'S TEST. Ordered test vill impact billing, including prior
	First Name	Last Name		DOB			<u>О</u> А	Asymptomatic O Symptoma	atic
Biological Mother								At GeneDx (Accession #:)
F	First Name	Last Name		DOB		_		Not available O To be sent w	
Biological						O Asymptomatic O Symptomatic O At GeneDx (Accession #:)	
	O Not available O To be sent within 3 weeks								
Relationship to Proband									
Other Biological	First Name	Last Name		DOB		-		Asymptomatic O Symptoma	ntic
Relative						O At GeneDx (Accession #:) O Not available O To be sent within 3 weeks			
CUSTOM SLICE TESTING OPTIONS									
TEST CODE TEST NAME TEST CODE TEST NAME TEST CODE TEST NAME									
	Slice - Single Gene (1 gene)					ODL		Slice - Homozygous (no gene	list)*
☐ TG70	Approved Slice ID:				Approved Slice ID:				
□ 706	Slice - Multi-Gene (2-150 ge Approved Slice ID:	enes)			☐ J757 Slice - Xpanded® (>150 Approved Slice ID:		Slice - Xpanded® (>150 genes, Approved Slice ID:	Proband or Trio*)	
* If a Trio or Duc	test is ordered, please fill out the	Family Mem	ber Samples to be Inclu	ided in Te	esting sec	ction c	abov	ve	
			SKIN I	DISORI	DER SL	ICES	5		
707	Slice - Epidermolysis Bullos	a (EB)			708		- 5	Slice - Congenital Ichthyosis	
· · · ·			REANALYSIS OF A						
before ordering		ent previousi	y naa a xome∪x® test (1						st one year from original/prior analysis
□ 660	XomeDx® First Time Reanalysis (no charge)				Reason for Reanalysis:				
947									
This is a second	la fan ambiant i i i				® XPER				
	le for patients with previous exomestitutional/self-pay only.	e anaiysis pe	rrormea by an outside o	ciinical lal	ooratory	wnere	∍as ——	second opinion is desired. Outside la	מג report requirea along with new
☐ TG56	XomeDx® Xpert (Proband o								
* If a Trio or Duc	test is ordered, please fill out the	Family Mem							
WRITE-IN TEST SELECTION									
☐ Test Code:		Tes	t Name:				_		

ACMG secondary findings, as discussed in the Informed Consent and Authorization Form, are only returned for the patient if an XomeDx* test (full exome analysis) is completed.

GeneDx tests are frequently updated and improved based upn the most recent scientific evidence. The test codes, genes, and gene quantities listed on this test requisition are subject to change by GeneDx at any time. The most current test menu and list of genes included for a specific test panel may be found on our website, genedx.com. Please note that GeneDx reserves the right to modify and upgrade any ordered panel to the version currently listed on our website.



GeneDx Account #		Ac	count Name				
First Name		La	st Name			Date of Birth	
			HISTO	RY			
FAMILY HISTORY:	Known Fami	ly History	□ Pedigree Att	ached	☐ Adopted		
Relationship	Maternal	Paterna	1	Relevan	t History		Age at Dx
1	0	0					
2	0	0					
3	0	0					
	_	•					
			PREVIOUS GENE	TIC TESTING			
Personal or family history of	genetic test	ing ()	No O Yes (If yes, plec	ise complete all fie	elds below)		
Relation to patient (self, sibli	ng, etc.), Ge	netic Test	t(s) and Result (e.g. posi	tive, negative, etc.). If relative was teste	ed at GeneDx, pleas	se also
provide their accession #:							
	If patient or relative(s) were found to have a positive or VUS result on prior testing, please provide details below.						
If patient or relative(s) were Indicate any Variants of Inte				r testing, please pr	rovide details below.		
Relation (self, sibling, etc.)	Gene	Transcr	ipt# c./p. (SNV)	or exon # (CNV)	Build, coord	linates (CNV)	Variant of Interest‡?
1							
2							
3							
Required for sequence variants: gen			'				
Required for CNVs: gene, transcript #	e, exon # <u>OR</u> buil	d, coordinat	es				
Abnormal karyotype, FISH, o	r other result	:s:					
‡ For certain tests, GeneDx may be ab	ole to specifically	/ comment ı	upon the presence or absence o	f previously identified va	riant(s) of interest in the re	port. Complete variant in	formation
must be provided in the table above on not be possible to comment upon the	at the time the te	est order is p	placed. If you do not complete th	e table above and chec	k off that a previously ident	ified variant is a variant o	

Continue to next page



GeneDx Account #	Account Name	
First Name	Last Name	Date of Birth
CLINICAL INFORM	MATION (DETAILED MEDICAL RECORDS MUS	ST BE ATTACHED)
Relevant clinical records are required at	the time of sample submission to ensure the	information is included in data analysis.
Gene of interest:		
Differential diagnosis:		
Pre/Perinatal History	Neurological Findings	Hearing Impairment
Cystic hygroma	Abnormality of nervous system	Abnormal Newborn Screen:
□ Diaphragmatic hernia		Conductive hearing impairment
□ Encephalocele □ Growth delay	□ Cerebral palsy □ Chorea	☐ Sensorineural hearing impairment
☐ Increased nuchal translucency	☐ Cortical Visual Impairment	
☐ Intrauterine Growth Retardation	□ Dementia	Endocrine Findings
□ Nonimmune hydrops fetalis	□ Dysarthria	☐ Delayed puberty
☐ Oligohydramnios .	□ Dyskinesia	□ Diabetes Insipidus □ Diabetes Mellitus
☐ Omphalocele	□ Dysphasia	☐ Hyperthyroidism
Polyhydramnios	□ Dystonia	☐ Hypophosphatemia
Prematurity GA:	☐ Encephalopathy	☐ Hypothyroidism
☐ Prolonged neonatal jaundice	☐ Headaches	☐ Maturity-onset diabetes of the young
	□ Hemiplegia □ Infantile Spasms	□Rickets
Structural Brain Abnormalies	☐ Migraines	
☐ Abnormal myelination	☐ Myoclonus	Pooningtony Findings
☐ Abnormality of basal ganglia	□ Parkinsonism	Respiratory Findings
☐ Abnormality of brainstem	□ Peripheral neuropathy	□ Asthma □ Bronchiectasis
Abnormality of periventricular white matter	☐ Seizures	☐ Hyperventilation
☐ Abnormality of the corpus callosum	□ Sensory neuropathy	☐ Hypoventilation
☐ Aplasia/hypoplasia of cerebellar vermis ☐ Aplasia/hypoplasia of cerebellum	□ Spasticity	☐ Pneumothorax
☐ Apidsid/hypopidsid of cerebellum ☐ Arnold Chiari malformation	Syncope	☐ Pulmonary fibrosis
☐ Cerebellar atrophy	☐ Tremors	☐ Respiratory insufficiency
☐ Heterotopia (Periventricular nodular	□ Vertigo	
heterotopia)		Hematologic or Immunologic Findings
□ Holoprosencephaly	Craniofacial/Dysmorphism	☐ Allergic rhinitis
□ Hydrocephalus	☐ Abnormal facial shape (Dysmorphic	☐ Anemia
Leukodystrophy	features) Specify:	— ☐ Immunodeficiency
Lissencephaly	☐ Brachycephaly	□Neutropenia
□ Pachygyria	Cleft lip and/or palate	□ Pancytopenia
☐ Polymicrogyria ☐ Ventriculomegaly	□ Coarse facial features □ Craniosynostosis	Recurrent infections
_ ventiledionlegaly	☐ Macrocephaly ☐ Microcephaly	□Thrombocytopenia
Developmental/Behavioral Findings	☐ Short neck	Skin/Hair Findings
☐ Absent speech	Synophrys	☐ Abnormal blistering of the skin
☐ Aggressive behavior		☐ Abnormality of nail
Anxiety	Two Defeate Wision	☐ Alopecia
Autistic Behavior	Eye Defects/Vision	☐ Anhidrosis
Cognitive impairment	☐ Abnormality of Vision	Café-Au-Lait Macules
Delayed speech & language development	□ Anophthalmia □ Cataracts	☐ Coarse hair
☐ Developmental regression ☐ Dysarthria		☐ Cutis Laxa
☐ Gait disturbance	☐ Corneal opacity	□ Eczema
□ Clobal dovelopmental delay	□ Ectonia lentis	☐ Hemangiomas

☐ Memory impairment ☐ Sleep disturbance ☐ Stereotypy

□ Hyperactivity

☐ Incoordination☐ Intellectual disability

☐ Learning disability

- ☐ External ophthalmoplegia
- ☐ Microphthalmia
- ☐ Myopia
 ☐ Nystagmus
- ☐ Optic atrophy
- ☐ Optic neuropathy
- ☐ Ptosis
- ☐ Retinal detachment
- □ Retinitis pigmentosa
- ☐ Strabismus

- ☐ Hyperextensible skin☐ Hyperpigmentation of the skin☐ Hypohidrosis
- ☐ Hypopigmentation of the skin
- ☐ Ichthyosis ☐ Skin rash
- \square Sparse hair

- ☐ Telangiectasia☐ Vascular skin abnormality
- □ Velvety skin



GeneDx Account #	Account Name	
First Name	Last Name	Date of Birth

CLINICAL INFORMATION (DETAILED MEDICAL RECORDS MUST BE ATTACHED)

Cardiac Findings	Musculoskeletal Findings	Vascular System
□ Abnormal heart morphology	☐ Abnormal connective tissue	□Aneurysm
□ Amyloidosis	☐ Abnormal form of the vertebral bodies	☐ Arterial calcification
□ Aortic root dilation	☐ Abnormality of the ribs	☐ Arterial dissection
□ Arrhythmia	☐ Arachnodactyly	☐ Arterial tortuosity
□ Atrial septal defect	☐ Arthralgia	☐ Arteriovenous malformation
□ Bicuspid aortic valve	☐ Arthrogryposis	□ Epistaxis
□ Bradycardia	☐ Bruising susceptibility	Lymphedema
☐ Coarctation of aorta	☐ Clinodactyly	Pulmonary hypertension
☐ Dilated cardiomyopathy	Decreased muscle mass	☐ Stroke
☐ Heterotaxy	☐ Ectrodactyly	□ otroke
☐ Hypertension	☐ Exercise intolerance	
☐ Hypertension ☐ Hypertrophic cardiomyopathy	☐ Fatigue	Cancer
☐ Hypertrophic cardiornyopatriy ☐ Mitral valve prolapse	☐ Hemihypertrophy	Cancer
		□ Type:
□ Noncompaction cardiomyopathy □ Patent ductus arteriosis	☐ Hypertonia	Location:
	Hypotonia	Age of onset:
□ Patent foramen ovale	☐ Joint hypermobility	, igo or onoci:
□ Prolonged QTc interval	☐ Muscle weakness	
□ Sudden death	☐ Myalgia	
☐ Tetralogy of Fallot	☐ Myopathic facies	
□ Ventricular septal defect	Myopathy	Other Testing/Imaging
□ Ventricular tachycardia	Osteoarthritis	(Please provide copy or report if possible)
	□ Osteopenia □ Pain	☐ Echo:
	□ Pectus carinatum	□ EEG:
Gastrointestinal Findings	Pectus excavatum	□ EMG:
□ Constipation	□ Polydactyly	
□ Diarrhea	Recurrent fractures	☐ MRI:
□ Duodenal stenosis/atresia	☐ Rhabdomyolysis	☐ Muscle Biopsy:
□ Exocrine pancreatic insufficiency	Scoliosis	□ Ultrasound:
□ Failure to thrive	☐ Short stature	□ X-rays:
☐ Feeding difficulties	☐ Skeletal dysplasia	
□ Gastroesophageal reflux	☐ Syndactyly	
□ Hepatomegaly ¯	☐ Tall stature	
□ Inflammatory bowel disease	rail statule	
		Additional Clinical Findings:
 □ Laryngomalacia		
□ Nausea	Metabolic Findings	
□ Pancreatitis	(Attached relevant lab reports/values)	
□ Pyloric stenosis	☐ Abnormal activity of mitochondrial	
, □ Splenomegaly	respiratory chain	
□ Tracheoesohageal fistula	□ Abnormal Newborn Screen:	
□ Vomiting	☐ Abnormality of mitochondrial metabolism	
	□ Elevated CPK	
	☐ Elevated hepatic transaminase	
	☐ Hyperammonemia	
Genitourinary Findings	☐ Hyperglycemia	
□ Ambiguous genitalia	☐ Hypoammonemia	
□ Cryptorchidism	☐ Hypoglycemia	
□ Cystic renal dysplasia	☐ Increased serum pyruvate	
☐ Horseshoe kidney	☐ Lactic acidosis	
☐ Hydronephrosis	☐ Plasma AA:	
☐ Hypospadias	Urine OA:	
□ Inguinal hernia		

□ Nephrolithiasis

☐ Renal agenesis ☐ Umbilical hernia

□ Polycystic kidney disease

INFORMED CONSENT



GeneDx Account #	Account Name	
First Name	Last Name	Date of Birth

For the purposes of this consent, "I", "my", and "your" will refer to me or to my child, including my unborn child, if my child is the person for whom the healthcare provider has ordered testing.

PURPOSE OF THIS TEST

The purpose of this test is (a) to see if I may have a genetic variant or chromosome rearrangement causing a genetic disorder; or (b) to evaluate the chance that I will develop or pass on a genetic disorder in the future. If I already know the specific gene variant(s) or chromosome rearrangement that causes the genetic disorder in my family, I agree to inform the laboratory of this information.

WHAT TYPE OF TEST RESULTS CAN I EXPECT FROM GENETIC TESTING?

- 1. Positive: A change in your DNA was found, which is very likely the cause of your features/symptoms. This is the most straightforward test result, which can be used as the basis to test other family members to determine their chances of having either the disease or a child with the disease.
- 2. Negative: No variants were found to explain your symptoms. This does not mean that you do not have a genetic condition. It is still possible that there is a genetic variant not found by the test that was ordered. Your healthcare provider or genetic counselor may discuss more testing either now or in the future.
- 3. <u>Variant of Uncertain Significance (VUS)</u>: A change in a gene was found. However, we are not sure whether this variant is the cause of your symptoms/features. More information is needed. We may suggest testing other family members to help figure out the meaning of the test result.
- 4. <u>Unexpected Results</u>: In rare instances, this test may reveal an important genetic change that is not directly related to the reason for ordering this test. For example, this test may find you are at risk for another genetic condition I am not aware of or it may indicate differences in the number or rearrangement of sex chromosomes. We may disclose this information to the ordering healthcare provider if it likely affects medical care.

Because medical and scientific knowledge is constantly changing, new information that becomes available may supplement the information GeneDx used to interpret my results. Healthcare providers can contact GeneDx at any time to discuss the classification of an identified variant.

WHAT IS TRIO/DUO-BASED GENETIC TESTING?

For some genetic tests, including samples from the biological parents and/or other biological relatives along with the patient's sample can help with the interpretation of the test results. These tests are often referred to as "trio tests" since they typically include samples from the patient and both parents.

Samples from relatives should be submitted with the patient's sample. Clinical information must be provided for the patient and any relative who submits a sample.

I understand that GeneDx will use the relative sample(s) when needed for the interpretation of my test results and that my test report may include clinical and genetic information about a relative when it is relevant to the interpretation of the test results. I further understand that relatives will not receive an independent analysis of data nor a separate report.

RISKS AND LIMITATIONS OF GENETIC TESTING

- 1. In some cases, testing may not identify a genetic variant even though one exists. This may be due to limitations in current medical knowledge or testing technology.
- 2. Accurate interpretation of test results may require knowing the true biological relationships in a family. I understand that if I fail to accurately state the biological relationships in my family, it could lead to incorrect interpretation of the test results, incorrect diagnoses, and/or inconclusive test results. If genetic testing reveals that the true biological relationships in a family are not as I reported them, including non-paternity (the reported father is not the biological father) and consanguinity (the parents are related by blood), I agree to have these findings reported to the healthcare provider who ordered the test.
- 3. Although genetic testing is highly accurate, inaccurate results may occur. These reasons include, but are not limited to mislabeled samples, inaccurate reporting of clinical/medical information, rare technical errors, or other reasons.
- 4. I understand that this test may not detect all of the long-term medical risks that I might experience. The result of this test does not guarantee my health and that additional diagnostic tests may still need to be done.
- 5. I agree to provide an additional sample if the initial sample is not adequate.

PATIENT CONFIDENTIALITY AND GENETIC COUNSELING

It is recommended that I receive genetic counseling before and after having this genetic test. I can find a genetic counselor in my area at www.nsgc.org. Further testing or additional consultations with a healthcare provider may be necessary.

To maintain confidentiality, test results will only be released to the referring healthcare provider, the ordering laboratory, to me, to other healthcare providers involved in my care, diagnosis and treatment, or to others with my consent or as permitted or required by law. Federal laws prohibit unauthorized disclosure of this information. More information can be found at: www.genome.gov/10002077

INTERNATIONAL SAMPLES

If I reside outside the United States, I attest that by providing a sample for testing, I am not knowingly violating any export ban or other legal restriction in the country of my residence.

SAMPLE RETENTION

After testing is complete, my sample may be de-identified and be used for test development and improvement, internal validation, quality assurance, and training purposes. GeneDx will not return DNA samples to you or to referring healthcare providers, unless specific prior arrangements have been made.

I understand that samples from residents of New York State will not be included in the de-identified research studies described in this authorization and GeneDx will not retain them for more than 60 days after test completion, unless specifically authorized by my selection. The authorization is optional, and testing will be unaffected if I do not check the box for the New York authorization language. GeneDx will not perform any tests on the biological sample other than those specifically authorized.

DATABASE PARTICIPATION

De-identified health history and genetic information can help healthcare providers and scientists understand how genes affect human health. Sharing this deidentified information helps healthcare providers to provide better care for their patients and researchers to make new discoveries. GeneDx shares this type of information with healthcare providers, scientists, and healthcare databases. GeneDx will not share any personally identifying information and will replace the identifying information with a unique code not derived from any personally identifying information. Even with a unique code, there is a risk that I could be identified based on the genetic and health information that is shared. GeneDx believes that this is unlikely, though the risk is greater if I have already shared my genetic or health information with public resources, such as genealogy websites.

INFORMED CONSENT



GeneDx Account #	Account Name	
First Name	Last Name	Date of Birth

EXOME/GENOME SEQUENCING SECONDARY FINDINGS

- Applicable Only for Full Exome Sequencing and Genome Sequencing Tests.
- Does not pertain to Xpanded® or Slice tests

As many different genes and conditions are analyzed in an exome or genome sequencing test, these tests may reveal some findings not directly related to the reason for ordering the test. Such findings are called "incidental" or "secondary" and can provide information that was not anticipated.

Secondary findings are variants, identified by an exome or genome sequencing test, in genes that are unrelated to the individual's reported clinical features.

The American College of Medical Genetics and Genomics (ACMG) has recommended that secondary findings identified in a specific subset of medically actionable genes associated with various inherited disorders be reported for all probands undergoing exome or genome sequencing. Please refer to the latest version of the ACMG recommendations for reporting of secondary findings in clinical exome and genome sequencing for complete details of the genes and associated genetic disorders. Reportable secondary findings will be confirmed by an alternate test method when needed.

WHAT WILL BE REPORTED FOR THE PATIENT?

All pathogenic and likely pathogenic variants associated with specific genotypes identified in the genes (for which a minimum of 10X coverage was achieved by exome sequencing or a minimum of 15X coverage was achieved by genome sequencing), as recommended by the ACMG.

WHAT WILL BE REPORTED FOR RELATIVES?

The presence or absence of any secondary finding(s) reported for the proband will be provided for all relatives analyzed by an exome or genome sequencing test.

LIMITATIONS

Pathogenic and/or likely pathogenic variants may be present in a portion of the gene not covered by this test and therefore are not reported. The absence of reportable secondary findings for any particular gene does not mean there are no pathogenic and/or likely pathogenic variants in that gene. Pathogenic variants and/or likely pathogenic variants that may be present in a relative, but are not present in the proband, will not be identified nor reported. Only changes at the sequence level will be reported in the secondary findings report. Larger deletions/duplications, abnormal methylation, triplet repeat or other expansion variants, or other variants not routinely identified by clinical exome and genome sequencing will not be reported.

FINANCIAL AGREEMENT AND GUARANTEE

For insurance billing, I understand and authorize GeneDx to bill my health insurance plan on my behalf, to release any information required for billing, and to be my designated representative for purposes of appealing any denial of benefits. I irrevocably assign to and direct that payment be made directly to GeneDx.

I understand that my out-of-pocket costs may be different than the estimated amount indicated to me by GeneDx as part of a benefit investigation. I agree to be financially responsible for any and all amounts as indicated on the explanation of benefits issued by my health insurance plan. If my insurance provider sends a payment directly to me for services performed by GeneDx on my behalf, I agree to endorse the insurance check and forward it to GeneDx within 30 days of receipt as payment towards GeneDx's claim for services rendered.

If I do not have health insurance, I agree to pay for the full cost of the genetic testing that was ordered by my healthcare provider and billed to me by GeneDx. I further understand and agree that, if I fail to make payment for genetic testing, in accordance with the payment policies of GeneDx, my account may be turned over to an external collection agency for non-payment. I agree to pay any associated collection costs, including attorney fees. By my signature on the GeneDx Test Requisition Form or at the bottom of this form, I accept full and complete financial responsibility for all genetic testing ordered by my healthcare provider.

MEDICARE

A completed Advance Beneficiary Notice (ABN) is required for Medicare patients, when applicable. Please visit our website, www.genedx.com/billing for more information.